The trials included those with “early symptomatic Alzheimer's disease”—either mild dementia or mild cognitive impairment (MCI) with evidence of raised amyloid levels and, in the donanemab trial, additional evidence of raised tau. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.